Succinate Dehydrogenase-Deficient Renal Cell Carcinoma: Clinicopathological Analysis of 11 Cases

PAN Xiuyi, WEI Yuyan, SUI Xiaochen, YIN Xiaoxue, ZHENG Linmao, ZENG Hao, ZHOU Qiao, CHEN Ni

Abstract

To investigate the clinicopathological features, immunophenotypes, molecular genetic alterations, and prognosis of succinate dehydrogenase-deficient renal cell carcinoma (SDH-RCC).

Methods 

A total of 11 cases of SDH-RCC diagnosed at West China Hospital, Sichuan University between 2016 and 2023 were selected for clinicopathological, immunohistochemical, and DNA sequencing analyses.

Results 

Among the 11 cases of SDH-RCC, there were 5 male patients and 6 female patients. The patients' ages ranged from 12 to 71 years, with an average age of 39.7 years. Among them, 5 patients had tumors located in the right kidney, 5 had tumors located in the left kidney, and 1 patient had bilateral tumors. Microscopic observation showed that the tumor cells of the SDH-RCC patients displayed a wide spectrum of structures, forming sheet-like, nested, and glandular structures. In addition, tumor cells in papillary structures were observed in some cases. The tumor cells had abundant cytoplasm, was eosinophilic, and contained flocculent materials. Intracytoplasmic vacuolations were observed in some of the cells. Among all the patients, 7 (7/11, 63.6%) showed typical low-grade features (grade 1-2 according to the International Society of Urological Pathology [ISUP]/WHO 2016 classification), and 4 (4/11, 36.4%) showed high-grade features (grade 3 according to the ISUP/WHO 2016 classification). The average ages of patients with low-grade and high-grade features were 32.1 years and 58.0 years, respectively. Immunohistochemical staining of all 11 cases demonstrated negative results for SDHB and cytokeratin 7 (CK7), and positive staining results for paired box 8 (PAX-8), fumarate hydratase (FH), and epithelial membrane antigen (EMA). Their Ki-67 index was 1%-30%. In one case, the loss of SDHB expression was also accompanied by a loss of SDHA expression. Sanger sequencing was performed to examine all the exons of SDHB in 7 cases. One case showed a frameshift mutation, c.236Tdel (p.K80Rfs*), and another case harbored a missense mutation, c.725G>A (p.Arg242His). In another case, next generation sequencing revealed that large fragments of SDHB (Exon 4-8 del) were missing. Follow-up data were available for 10 patients. The follow-up time ranged from 4 to 138 months, with the average being 32.8 months, and all patients survived. Metastasis and recurrence were reported in 5 cases, with 3 of them showing high-grade features and 2 showing low-grade features.

Conclusion 

SDH-RCC is rare and the patients demonstrate a relatively young age of onsets. Patients may present with bilateral tumors. Tumors with low-grade features usually occur in young patients, with their Ki-67 index usually being lower than 5%. Individual cases may experience tumor recurrence and metastasis over a long period of follow-up. Tumors with high-grade features tend to occur in older patients who have a higher Ki-67 index, and who are prone to recurrence and metastasis. Negative immunohistochemical staining results for SDHB can assist in tumor diagnosis, but the loss of SDHB protein expression does not necessarily lead to the detection of SDHB gene mutation.

 

Keywords: Succinate dehydrogenase-deficient renal cell carcinoma, Gene mutation, Clinicopathological characteristics, Prognosis

 

Full Text:

PDF


References


GILL A J. Succinate dehydrogenase (SDH) and mitochondrial driven neoplasia. Pathology, 2012, 44(4): 285–292. doi: 10.1097/PAT. 0b013e3283539932.

ALDERA A P, GOVENDER D. Gene of the month: SDH. J Clin Pathol, 2018, 71(2): 95–97. doi: 10.1136/jclinpath-2017-204677.

DALLA POZZA E, DANDO I, PACCHIANA R, et al. Regulation of succinate dehydrogenase and role of succinate in cancer. Semin Cell Dev Biol, 2020, 98: 4–14. doi: 10.1016/j.semcdb.2019.04.013.

FUCHS T L, MACLEAN F, TURCHINI J, et al. Expanding the clinicopathological spectrum of succinate dehydrogenase-deficient renal cell carcinoma with a focus on variant morphologies: a study of 62 new tumors in 59 patients. Mod Pathol, 2022, 35(6): 836–849. doi: 10.1038/s41379-021-00998-1.

GILL A J, HES O, PAPATHOMAS T, et al. Succinate dehydrogenase (SDH)-deficient renal carcinoma: a morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients. Am J Surg Pathol, 2014, 38(12): 1588–1602. doi: 10.1097/PAS.0000000000000292.

MOCH H, AMIN M B, BERNEY D M, et al. The 2022 World Health Organization classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours. Eur Urol, 2022, 82(5): 458–468. doi: 10.1016/j.eururo.2022.06.016.

VANHARANTA S, BUCHTA M, MCWHINNEY S R, et al. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. Am J Hum Genet, 2004, 74(1): 153–159. doi: 10.1086/381054.

KAMAI T, HIGASHI S, MURAKAMI S, et al. Single nucleotide variants of succinate dehydrogenase A gene in renal cell carcinoma. Cancer Sci, 2021, 112(8): 3375–3387. doi: 10.1111/cas.14977.

SUN X, WANG G, HUANG Z, et al. Succinate dehydrogenase defects giant renal cell carcinoma. Urol Int, 2023, 107(8): 819–822. doi: 10.1159/ 000531059.

MAHER E R. Hereditary renal cell carcinoma syndromes: diagnosis, surveillance and management. World J Urol, 2018, 36(12): 1891–1898. doi: 10.1007/s00345-018-2288-5.

WILCZEK Y, SACHDEVA A, TURNER H, et al. SDH-deficient renal cell carcinoma: a clinicopathological analysis highlighting the role of genetic counselling. Ann R Coll Surg Engl, 2021, 103(1): e20–e22. doi: 10.1308/rcsann.2020.0196.

WILLIAMSON S R, EBLE J N, AMIN M B, et al. Succinate dehydrogenase-deficient renal cell carcinoma: detailed characterization of 11 tumors defining a unique subtype of renal cell carcinoma. Mod Pathol, 2015, 28(1): 80–94. doi: 10.1038/modpathol.2014.86.

ROGALA J, ZHOU M. Hereditary succinate dehydrogenase-deficient renal cell carcinoma. Semin Diagn Pathol, 2024, 41(1): 32–41. doi: 10.

TSAI T H, LEE W Y. Succinate dehydrogenase-deficient renal cell carcinoma. Arch Pathol Lab Med, 2019, 143(5): 643–647. doi: 10.5858/arpa.2018-0024-RS.

ALBERTSON D, BARRY M, LIU T, et al. Genotype phenotype correlation of renal tumors in the cancer genome atlas database. Int J Surg Pathol, 2024: 10668969241260236. doi: 10.1177/10668969241260236.

WILLIAMS G M, LYNCH D T. Renal Oncocytoma. Treasure Island (FL): StatPearls Publishing, 2024.

BAGHDADI A, ALDHAAM N A, ELSAYED A S, et al. Automated differentiation of benign renal oncocytoma and chromophobe renal cell carcinoma on computed tomography using deep learning. BJU Int, 2020, 125(4): 553–560. doi: 10.1111/bju.14985.

YOUSEF A, KIM S S, KRIZOVA A. CAIX immunostaining in non-neoplastic renal diseases. Cancer Diagn Progn, 2022, 2(6): 661–667. doi: 10.21873/cdp.10157.

GARJE R, ELHAG D, YASIN H A, et al. Comprehensive review of chromophobe renal cell carcinoma. Crit Rev Oncol Hematol, 2021, 160: 103287. doi: 10.1016/j.critrevonc.2021.103287.

HENSKE E P, CHENG L, HAKIMI A A, et al. Chromophobe renal cell carcinoma. Cancer Cell, 2023, 41(8): 1383–1388. doi: 10.1016/j.ccell.2023. 07.006.

ALAGHEHBANDAN R, PRZYBYCIN C G, VERKARRE V, et al. Chromophobe renal cell carcinoma: Novel molecular insights and clinicopathologic updates. Asian J Urol, 2022, 9(1): 1–11. doi: 10.1016/j. ajur.2021.11.010.

LAU H D, CHAN E, FAN A C, et al. A clinicopathologic and molecular analysis of fumarate hydratase-deficient renal cell carcinoma in 32 patients. Am J Surg Pathol, 2020, 44(1): 98–110. doi: 10.1097/PAS. 0000000000001372.

PAN X, ZHANG M, YAO J, et al. Fumaratehydratase-deficient renal cell carcinoma: a clinicopathological and molecular study of 13 cases. J Clin Pathol, 2019, 72(11): 748–754. doi: 10.1136/jclinpath-2019-205924.

GUPTA S, SWANSON A A, CHEN Y B, et al. Incidence of succinate dehydrogenase and fumarate hydratase-deficient renal cell carcinoma based on immunohistochemical screening with SDHA/SDHB and FH/2SC. Hum Pathol, 2019, 91: 114–122. doi: 10.1016/j.humpath.2019.07. 004.

ZHENG L, ZHANG X, PAN X, et al. AKR1B10 is a new sensitive and specific marker for fumarate hydratase-deficient renal cell carcinoma. Mod Pathol, 2023, 36(11): 100303. doi: 10.1016/j.modpat.2023.100303.

SHI S S, WANG Y F, BAO W, et al. Genetic and epigenetic alterations of SDH genes in patients with sporadic succinate dehydrogenase-deficient gastrointestinal stromal tumors. Pathol Int, 2019, 69(6): 350–359. doi: 10. 1111/pin.12809.

LIU J, WANG Y, WANG X, et al. Succinate dehydrogenase A deficient renal cell carcinoma: a rare renal tumor distinct from typical succinate dehydrogenase deficient renal cell carcinoma. Pathol Res Pract, 2024, 261: 155459. doi: 10.1016/j.prp.2024.155459.


Refbacks

  • There are currently no refbacks.